CHAMPIONS ONCOLOGY, INC. Increase (Decrease) in Contract with Customer, Liability
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Increase (Decrease) in Contract with Customer, Liability of $724.00 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-09-11
- CHAMPIONS ONCOLOGY, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-07-31 was $724.00K.
- CHAMPIONS ONCOLOGY, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-04-30 was -$1.17M, a 125.88% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-01-31 was -$2.34M, a 433.33% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-10-31 was -$2.09M.
- CHAMPIONS ONCOLOGY, INC. increase (decrease) in contract with customer, liability for fiscal 2026 was -$6.62M, a 297.52% decline from fiscal 2025.
- CHAMPIONS ONCOLOGY, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was $3.35M.
- CHAMPIONS ONCOLOGY, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was -$683.00K, a 140.04% decline from fiscal 2023.
- CHAMPIONS ONCOLOGY, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was $1.71M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-07-31 | $724.00K 10-Q · filed 2026-09-11 | -$446.00K derived: sum of 2 quarters · filed 2026-09-11 | -$2.79M derived: sum of 3 quarters · filed 2026-09-11 | -$4.88M derived: sum of 4 quarters · filed 2026-09-11 |
| 2026-04-30 | -$1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-27 | -$3.51M derived: sum of 2 quarters · filed 2026-07-27 | -$5.60M derived: sum of 3 quarters · filed 2026-07-27 | -$6.62M 10-K · filed 2026-07-27 |
| 2026-01-31 | -$2.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-12 | -$4.43M derived: sum of 2 quarters · filed 2026-03-12 | -$5.45M 10-Q · filed 2026-03-12 | -$924.00K derived: sum of 4 quarters · filed 2026-09-11 |
| 2025-10-31 | -$2.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-15 | -$3.10M 10-Q · filed 2025-12-15 | $1.42M derived: sum of 3 quarters · filed 2026-09-11 | $2.12M derived: sum of 4 quarters · filed 2026-09-11 |
| 2025-07-31 | -$1.01M 10-Q · filed 2026-09-11 | $3.51M derived: sum of 2 quarters · filed 2026-09-11 | $4.21M derived: sum of 3 quarters · filed 2026-09-11 | $4.12M derived: sum of 4 quarters · filed 2026-09-11 |
| 2025-04-30 | $4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-27 | $5.22M derived: sum of 2 quarters · filed 2026-07-27 | $5.13M derived: sum of 3 quarters · filed 2026-07-27 | $3.35M 10-K · filed 2026-07-27 |
| 2025-01-31 | $702.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-12 | $610.00K derived: sum of 2 quarters · filed 2026-03-12 | -$1.17M 10-Q · filed 2026-03-12 | -$2.41M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-10-31 | -$92.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-15 | -$1.87M 10-Q · filed 2025-12-15 | -$3.11M derived: sum of 3 quarters · filed 2025-12-15 | -$2.75M derived: sum of 4 quarters · filed 2025-12-15 |
| 2024-07-31 | -$1.78M 10-Q · filed 2025-09-15 | -$3.02M derived: sum of 2 quarters · filed 2025-09-15 | -$2.66M derived: sum of 3 quarters · filed 2025-09-15 | -$831.00K derived: sum of 4 quarters · filed 2025-09-15 |
| 2024-04-30 | -$1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-23 | -$874.00K derived: sum of 2 quarters · filed 2025-07-23 | $951.00K derived: sum of 3 quarters · filed 2025-07-23 | -$683.00K 10-K · filed 2025-07-23 |
| 2024-01-31 | $362.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-03-17 | $2.19M derived: sum of 2 quarters · filed 2025-03-17 | $553.00K 10-Q · filed 2025-03-17 | $171.00K derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-10-31 | $1.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-12-16 | $191.00K 10-Q · filed 2024-12-16 | -$191.00K derived: sum of 3 quarters · filed 2024-12-16 | $1.78M derived: sum of 4 quarters · filed 2024-12-16 |
| 2023-07-31 | -$1.63M 10-Q · filed 2024-09-13 | -$2.02M derived: sum of 2 quarters · filed 2024-09-13 | -$42.00K derived: sum of 3 quarters · filed 2024-09-13 | $258.00K derived: sum of 4 quarters · filed 2024-09-13 |
| 2023-04-30 | -$382.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-19 | $1.59M derived: sum of 2 quarters · filed 2024-07-19 | $1.89M derived: sum of 3 quarters · filed 2024-07-19 | $1.71M 10-K · filed 2024-07-19 |
| 2023-01-31 | $1.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-03-15 | $2.27M derived: sum of 2 quarters · filed 2024-03-15 | $2.09M 10-Q · filed 2024-03-15 | |
| 2022-10-31 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-12-13 | $114.00K 10-Q · filed 2023-12-13 | ||
| 2022-07-31 | -$186.00K 10-Q · filed 2023-09-13 | |||
| 2022-01-31 | $2.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-03-16 | $3.22M derived: sum of 2 quarters · filed 2023-03-16 | $2.44M 10-Q · filed 2023-03-16 | |
| 2021-10-31 | $651.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-12-13 | -$124.00K 10-Q · filed 2022-12-13 | ||
| 2021-07-31 | -$775.00K 10-Q · filed 2022-09-12 | |||
| 2021-01-31 | $428.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-03-15 | $947.00K derived: sum of 2 quarters · filed 2022-03-15 | $801.00K 10-Q · filed 2022-03-15 | |
| 2020-10-31 | $519.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-12-13 | $373.00K 10-Q · filed 2021-12-13 | ||
| 2020-07-31 | -$146.00K 10-Q · filed 2021-09-13 | |||
| 2020-01-31 | $440.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-03-15 | $617.00K derived: sum of 2 quarters · filed 2021-03-15 | $564.00K 10-Q · filed 2021-03-15 | |
| 2019-10-31 | $177.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-12-14 | $124.00K 10-Q · filed 2020-12-14 | ||
| 2019-07-31 | -$53.00K 10-Q · filed 2020-09-14 | |||
| 2019-01-31 | -$105.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-03-16 | $460.00K derived: sum of 2 quarters · filed 2020-03-16 | $19.00K 10-Q · filed 2020-03-16 | |
| 2018-10-31 | $565.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-12-16 | $124.00K 10-Q · filed 2019-12-16 | ||
| 2018-07-31 | -$441.00K 10-Q · filed 2019-09-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |